Gamma knife radiosurgery (GKRS) evolved from the vision of Lars Leksell as a method of bloodless surgery for treating a wide variety of intracranial pathologies. Since the first GKRS procedure for trigeminal neuralgia (TN) in the early 1970s, thousands of medically refractory patients have been treated, with good results. GKRS has become a first-line treatment for medically refractory TN along with microvascular decompression and percutaneous rhizotomy. GKRS offers the advantages of minimal invasiveness and extremely low risk. When recommending a surgical treatment modality for medically refractory TN, one must consider patient preferences, procedural risks, medical co-morbidities and the success rates of the various approaches. In this context, we review the role of GKRS in the treatment of medically refractory TN.
What is Trigeminal Neuralgia?
Trigeminal neuralgia (TN) is a vexing clinical problem for a number of reasons, not least of which is clearly defining its clinical spectrum.
A commonly accepted definition of TN is that of a facial pain syndrome in which a patient experiences brief, episodic and sharp attacks of pain in the distribution of the trigeminal nerve. These painful attacks are typically unilateral but can rarely be bilateral. Painful attacks are often brought on by triggers including chewing or touching the affected dermatome. Atypical TN includes more lingering or non-episodic constant pain that does not have the typical tactile triggers. Moreover, atypical facial pain, often bilateral, can present in the context of somatoform disorders in which no organic cause can be identified.
Finally, one or more of these different types of pain can be present in the same patient at the same time. It is important to distinguish between these different types of facial pain because their aetiologies are probably different and thus their treatments as well.
Burchiel's recent classification scheme, with minor modifications, links the nature of the trigeminal pain with possible mechanisms (see Table 1 ). 1 In this scheme, what has been known as tic douloureux or typical (type 1) TN is characterised by primarily episodic painful attacks located in the distribution of the trigeminal nerve branches.
When constant or lingering pain is the predominant feature but there are additional episodic features, the syndrome is called type 2 TN.
These idiopathic forms are distinguished from the deafferentation pain syndromes caused by either unintentional (i.e. accidental trauma) or intentional (purposeful surgical injury to the nerve) damage to the trigeminal nerve. Facial pain following a herpes zoster outbreak falls into this condition as well. These latter conditions are associated with demonstrable trigeminal sensory loss. Finally, somatoform facial pain is labeled atypical facial pain, and is characterised by its bilaterality, as well as presence of pain well outside of the innervation of the trigeminal nerve. Unless otherwise specified, this article is focused on the paroxysmal trigeminal pain syndromes including types 1 and 2 TN as well as TN caused by multiple sclerosis (MS). None of the therapies covered in this article has meaningful benefit for constant or deafferentation facial pain.
Although TN has an annual incidence of 27 per 100,000, 2 the mechanism underlying its episodic facial pain remains incompletely understood.
In many patients, it is related to vascular compression of the trigeminal nerve by branches of the superior cerebellar artery 3, 4 or, less commonly, adjacent veins. How this mediates pain transmission is not clear, but it has been postulated that vascular compression results in local demyelination and axonopathy, which results in ephaptic transmission between the damaged heavily myelinated fibres and the smaller unmyelinated pain fibres. 5 This finding has led to the use of microvascular decompression (MVD) surgery as a primary treatment for TN, one that attacks the aetiology in a significant number of patients.
Patients with MS suffer from TN at a rate several-fold higher than the general population (2 %). 6 Demyelination along the trigeminal system due to the underlying autoimmune phenomenon is implicated, but 75 % of patients report excellent results (defined as 98 % decrease in pain and off medications) with another 9 % reporting a good outcome (a 75 % decrease in pain and on low-dose medication). At 10 years, 64 % continued to have excellent outcomes, while 4 % had good outcomes. However, the major complication rate following MVD was around 8 %, including permanent neurological deficit, cerebrospinal fluid leak, bacterial meningitis and death. Thus, although MVD is a highly effective therapy and patients often respond immediately, it has associated risks that relate in part to the experience and skill of the surgeon who performs the procedure. Unfortunately, due to advanced age or medical co-morbidities, not all patients are candidates for MVD.
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For patients who are unable or unwilling to tolerate the risks associated with MVD, several different percutaneous rhizotomy procedures are available. The first percutaneous therapy directed at the gasserian ganglion is credited to Harris in 1910. 13 These first procedures involved the injection of alcohol into the ganglion and were successful in producing pain relief but at the expense of often profound anaesthesia of the face and resultant deafferentation pain in some patients. Recurrences of TN were treated by additional injections when necessary. 13 Unfortunately, this early technique was associated with other potential morbidity, including spread of the alcohol within the cerebrospinal fluid and resultant damage to other cranial nerves. Percutaneous radiofrequency rhizotomy is also associated with the risk of a diminished corneal reflex, masseter weakness, ansesthesia dolorosa, aseptic meningitis and herpes simplex reactivation.
Gamma Knife Radiosurgery for Trigeminal Neuralgia
Since the development of the gamma knife in the 1960s by Leksell and Larsson, the technology has evolved tremendously. All gamma knife instruments are based on the same fundamental principle:
closed-cranial irradiation of intracranial targets using multiple photon beams after localisation of the target(s) in stereotactic space. 18 GKRS was first used by Leksell to treat TN in 1971. 19 Since this initial experience, GKRS has been used to treat TN in thousands of patients worldwide. Unlike other TN treatments, GKRS is effectively non-invasive.
It is similar to the percutaneous techniques in that its mechanism treats the trigeminal nerve through lesioning and bypasses the cause (i.e. vascular compression). Interestingly, although GKRS is very effective at eliminating the paroxysmal pain of TN, the risk of facial anaesthesia or dysaesthesias is low. It was originally suggested that the mechanism Gamma Knife Radiosurgery for Trigeminal Neuralgia -A Review Histological evaluation of the trigeminal nerve in primates following GKRS showed axonal degeneration and mild oedema, with both large and small myelinated and unmyelinated axons seeing effects. 20 After a high radiation dose (100 Gy), nerve necrosis was identified. Thus these data demonstrated the effect of GKRS is non-selective.
Our experience at the University of Pittsburgh treating TN with GKRS has spanned nearly three decades. In our recent report by Kondziolka et al. we reviewed our 25-year experience in over 500 medically refractory patients with idiopathic TN. 21 The median age of this cohort was 72 and nearly half had recurrent pain after previous procedures.
Although the gasserian ganglion had previously been the radiosurgical target, the most common target at present is the cisternal portion of the trigeminal nerve. Specifically, the nerve was targeted 3-8 mm distal to its exit site from the pons. In the majority of patients, a single 4 mm isocentre was targeted to the nerve and a dose of 80-85 Gy was administered (see Figure 1) . In order to compare results across studies, many investigators have adopted the Barrow Neurological Institute (BNI) score as a standardised vehicle to indicate the success of a radiosurgical treatment (see Table 2 ). 22 Following GKRS, 89 % of patients initially responded to treatment (BNI scores I-IIIb) with a median latency of one month. Only 11 % failed to achieve a good result (BNI scores IV and V). anterior to the junction of the nerve with the pons such that the brainstem surface is irradiated at the 20 % isodose line or less. 21 The target is based on the variable distance between the pons and the cavernous sinus with the goal of minimising the dose to the lateral pons.
Which Patients Should Receive Which Therapy?
Choosing which patients should undergo GKRS for TN requires consideration of a number of factors including the suspected pain aetiology, patient age, surgical fitness, previous treatments, severity of pain, patient preference and understanding of each technique's success and complication rates. Ten years after initial MVD for medically refractory TN, 64 % of patients continue to have nearly complete relief of pain without the need for medication. 4 This is twice the rate of durable pain relief for GKRS after 10 years. 21 Cohort analyses comparing the efficacy of MVD versus GKRS have shown that MVD is superior to GKRS in achieving long-lasting pain relief. [31] [32] [33] Rates of sensory dysfunction were comparable, but patients undergoing GKRS were not exposed to any of the surgical morbidities. Another important difference lies in the rapidity with which relief takes effect.
Following MVD, most patients have immediate relief (i.e. upon waking from anaesthesia), 4 while the median time to pain relief following GKRS is approximately one month.
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MVD has also proven more effective in achieving complete and long-lasting pain relief when compared with percutaneous
The inner circle represents the 50 % isodose line (35 Gy) with percutaneous radiofrequency lesioning. 34 They found that with radiofrequency lesioning there was a 50 % risk of pain recurrence after two years, whereas 64 % of patients undergoing MVD were still pain-free after 20 years. A meta-analysis of 28 studies confirmed that MVD was superior to radiofrequency lesioning. 35 Taken together with the accepted vascular compression mechanism of TN, these results suggest that, for patients who are surgically fit and willing to accept the risks of surgery, MVD is the best approach to achieve long-lasting pain relief.
Henson et al. compared their results with glycerol rhizotomy and GKRS. 36 They observed that both procedures provided similar early pain relief rates (86 versus 92 %, respectively, for glycerol rhizotomy and GKRS), but that glycerol rhizotomy provided more rapid pain relief (<24 hours).
However, glycerol rhizotomy failed significantly more frequently in the long term and was associated with more facial sensory disturbance.
Percutaneous radiofrequency lesioning has similar rates of pain control (58 % pain-free after five years) but, like glycerol rhizotomy, possesses an increased risk of facial sensory dysfunction and dysaesthesias. 36, 17 Overall, percutaneous rhizotomy approaches achieve a more rapid onset of pain relief (i.e. immediate or within days), whereas GKRS takes around a month to take effect. In addition, although GKRS appears have a lower rate of long-term pain relief versus percutaneous approaches (i.e. 29 versus 52 %, respectively, long-term pain-free rate for GKRS and radiofrequency rhizotomy), 21, 17 GKRS has a greatly reduced risk of facial sensory dysfunction (i.e. 30 versus 54 %, respectively, for GKRS versus glycerol rhizotomy). 36 We recommend the use of percutaneous procedures in patients not medically fit for MVD and for whom pain is so severe that the latency period of GKRS is unacceptable. 15 The mechanism of TN in MS is felt to be related to autoimmune-mediated Table 3 ). 21 Similar findings have been observed in small cohorts by other groups. 40, 41 The advantage of GKRS in the setting of MS is its exquisitely low risk of complications, even when compared with the percutaneous techniques.
GKRS also has a role in the treatment of TN from other, less common causes. For example, vascular compression of the trigeminal nerve can be caused by vertebrobasilar ectasia (VBE) in up to 2 % of cases. 42 MVD in these circumstances has proven to be the most efficacious (i.e. in one series 96, 92, and 86 % pain-free rates at one, three and 10 years after the procedure, respectively), 43 but it can be technically more challenging. As a result, a high rate of surgical complications has been observed (11 % rate of new permanent neurological deficits). 43 respectively. These results are not as good as those for patients without VBE but, due to the minimal rate of complications, GKRS
should be considered as a reasonable option for these patients.
TN often recurs regardless of treatment approach. At least one-quarter of patients have pain recurrence after an initial MVD. 4 We have observed a recurrence rate of one-quarter to one-third in patients treated by glycerol rhizotomy 44 and approximately 40 % in patients treated by GKRS. 21 Thus, patients often require multimodality therapy and repeat procedures, even repeat GKRS. Park et al. evaluated the validity of a Gamma Knife Radiosurgery for Trigeminal Neuralgia -A Review repeat GKRS strategy after previous failed GKRS treatment for TN in 119 patients. 2 In this cohort, 54 % of patients had undergone previous surgical procedures in addition to their first GKRS procedure.
Following repeat GKRS, 32 % achieved complete pain relief (BNI score I) and 87 % achieved BNI scores I-IIIb pain control after a median latency of 1.5 months. Although 34 % of patients had pain recurrence, long-term pain control (BNI scores I-IIIb) was achieved in 88, 70, and 44 % of patients after one, three, and five years, respectively.
Twenty-one per cent of patients developed new or worsened facial sensory dysfunction, a rate twice the original procedure. Patients who had good relief from the initial GKRS procedure and those with some degree of facial sensory dysfunction had improved outcomes after repeat GKRS. These results suggest that repeat GKRS is a useful treatment modality, but is associated with an increased risk of facial sensory dysfunction.
Conclusions
TN is a debilitating condition for its sufferers and its management is, at times, not straightforward. Many patients will fail medical management and request some sort of surgical intervention. The vascular compression theory is well accepted and MVD has proven the most efficacious and longest lasting of the surgical options, but it is the most invasive and involves the greatest intrinsic risks. 
